No abstract available.
Angiogenesis Inducing Agents*

No abstract available.
Angiogenesis Inducing Agents* ; Intracranial Aneurysm*

No abstract availalbe.
Angiogenesis Inducing Agents* ; Vascular Endothelial Growth Factor A

Background: Current medical management of endometriosis leads to suppression of ovulation and will not be helpful for women with endometriosis who are desirous of pregnancy. Thus, drugs that can both treat endometriosis and its associated infertility are highly warranted. Objective: Anti-angiogenic agents are potential drugs for patients with endometriosis and infertility. Among these drugs, dopamine agonist (DA) is promising since it does not interfere with ovulation, is safe, and not teratogenic. The aim of the study is to determine the efficacy and safety of DA for improving reproductive outcomes in women with endometriosis and infertility. Methods: A qualitative narrative review was done from inception to July 31, 2022 using the appropriate MeSH terms in PubMed, Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, ClinicalTrial.gov, and World Health Organization International Clinical Trials Registry Platform. Date analysis was through qualitative analysis and synthesis of researches and their outcome measures. Results: No studies used the core outcomes for trials evaluating treatments for infertility associated with endometriosis. All the included articles in the review supported the possible anti-angiogenic effects of DA on the vascular endothelial growth factor [VEGF] /VEGF receptor system. The use of DA does not have an effect on ovulation and menstrual cyclicity. Studies on safety profile of DA were consistent with existing data. Conclusion Most of studies reviewed demonstrated that DA were effective in reducing endometriotic lesions. However, further research is required to establish whether this anti-angiogenic effect can improve reproductive outcomes in women with endometriosis-associated infertility.
Endometriosis ; Dopamine Agonists ; Infertility ; Angiogenesis Inducing Agents ; Angiogenesis Inhibitors

No abstract available.
Airway Remodeling ; Angiogenesis Inducing Agents ; Rhinitis ; Rhinitis, Allergic, Perennial

PURPOSE: VEGF is thought to be an important angiogenic factor playing significant a role in the aggressiveness of malignant tumor by stimulating neovascularization. We morphologically investicated the tumor angiogenesis in terms of the presence of VEGF expression in advanced gastric carcinoma. MATERIALS AND METHODS: We performed immunohistochemical stains for VEGF, CD 34, and MIB-1 (Ki-67) on the 51 paraffin-embedded tissue sections. The degree of angiogenesis was determined by counting microvessel densities and their Ki-67 labelling indices of endothelial cells within the tumors. We evaluated the correlation between the expression of VEGF, angiogenesis and clinicopathologic factors such as histologic differentiation, depth of invasion, and lymph node metastasis. RESULTS: Immunoreactivity for VEGF revealed positivity in 34 out of 51 cases (66.7%). Microvessel densities and Ki-67 labelling indices of endothelial cells reflecting angiogenesis were higher in VEGF-positive tumors than VEGF-negative tumors. There were no conelations between VEGF expression, histologic differentiation and the depth of invasion. We failed to evaluate the conelation of VEGF expression and lymph node metastasis. CONCLUSION: This study suggests that VEGF expressian is closely related to tumor asso- ciated angiogenesis in advanced gastric carcinoma. Considering that tumor growth depends on angiogenesis, therapies reducing VEGF may be a means of inhibiting angiogenesis and tumor aggressiveness.
Angiogenesis Inducing Agents ; Coloring Agents ; Endothelial Cells ; Lymph Nodes ; Microvessels ; Neoplasm Metastasis ; Vascular Endothelial Growth Factor A*

Sex hormone estrogen is one of the most active intrinsic angiogenesis regulators; its therapeutic use has been limited due to its carcinogenic potential. Plant-derived phytoestrogens are attractive alternatives, but reports on their angiogenic activities often lack in-depth analysis and sometimes are controversial. Herein, we report a data-mining study with the existing literature, using IPA system to classify and characterize phytoestrogens based on their angiogenic properties and pharmacological consequences. We found that pro-angiogenic phytoestrogens functioned predominantly as cardiovascular protectors whereas anti-angiogenic phytoestrogens played a role in cancer prevention and therapy. This bidirectional regulation were shown to be target-selective and, for the most part, estrogen-receptor-dependent. The transactivation properties of ERα and ERβ by phytoestrogens were examined in the context of angiogenesis-related gene transcription. ERα and ERβ were shown to signal in opposite ways when complexed with the phytoestrogen for bidirectional regulation of angiogenesis. With ERα, phytoestrogen activated or inhibited transcription of some angiogenesis-related genes, resulting in the promotion of angiogenesis, whereas, with ERβ, phytoestrogen regulated transcription of angiogenesis-related genes, resulting in inhibition of angiogenesis. Therefore, the selectivity of phytoestrogen to ERα and ERβ may be critical in the balance of pro- or anti-angiogenesis process.
Angiogenesis Inducing Agents ; metabolism ; Angiogenesis Inhibitors ; metabolism ; Animals ; Gene Expression Regulation ; Humans ; Phytoestrogens ; metabolism ; Receptors, Estrogen ; genetics ; metabolism ; Signal Transduction

Angiogenesis is a critical factor in the progression of solid tumors, including cervical cancers. The mechanisms responsible for angiogenesis in uterine cervical neoplasia are not well defined. To determine the relationship between angiogenesis and the expression of vascular endothelial growth factor (VEGF) in the cervical neoplasia, the author studied 63 cases of the cervical neoplasia diagnosed between the years 1993 to 1997 at Pusan National University Hospital. The expression of VEGF was semiquantitatively analyzed in paraffin sections by immunohistochemical method. Histologic sections immunostained for factor VIII-related antigen were evaluated for microvessel density. Increased expression of VEGF and microvessel counts was significantly correlated with depth of invasion. Increased microvessel counts were also significantly associated with increased VEGF expression. These results suggest that VEGF is an important angiogenic factor and associated with progression of the cervical neoplasia.
Angiogenesis Inducing Agents ; Busan ; Microvessels ; Paraffin ; Uterine Cervical Neoplasms ; Vascular Endothelial Growth Factor A* ; von Willebrand Factor

PURPOSE: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor in a number of cancers. The aim of this study was to evaluate the clinical significance of the serum level of VEGF in hepatocellular carcinoma (HCC) patients. METHODS: Serum VEGF was measured by an enzyme linked immunosorbent assay (ELISA) method. The correlation between serum VEGF level and clinico-pathological data of HCC patients were evaluated. RESULTS: The serum VEGF levels significantly increased with increasing tumor size and platelets count. The mean serum VEGF level in HCC patients with microvessel tumor invasion was higher than in those without microvessel tumor invasion. CONCLUSION: A high serum VEGF level may be an indicator of tumor progression and an important predictor of microvessel tumor invasion.
Angiogenesis Inducing Agents ; Carcinoma, Hepatocellular* ; Enzyme-Linked Immunosorbent Assay ; Humans ; Microvessels* ; Vascular Endothelial Growth Factor A*

PURPOSE: The precise role of angiogenesis in prostate cancer should be defined. Several reports suggest that thrombospondin-1 (TSP-1) possesses a tumor suppressor function, possibly through its ability to inhibit tumor neovascularization. The vascular endothelial growth factor (VEGF), one of the most important angiogenic factors in a solid tumor, has shown conflicting results on prostate cancer. Therefore, TSP-1 and VEGF expression in prostate cancer, and their relationship with the p53 status were analyzed. MATERIALS AND METHODS: Using immunohistochemistry, the expression of VEGF, TSP-1 and p53 was assessed in 75 archival tissues from 23 benign prostatic hyperplasia (BPH), 22 localized prostate cancer, and 30 metastatic prostate cancer patients. The relationship between VEGF and TSP-1, and the p53 status, tumor grade and stage was evaluated in patients with prostate cancer. RESULTS: The immunohistochemical analysis demonstrated a higher VEGF expression level (p<0.01) and a lower TSP-1 expression level (p<0.01) in prostate cancer compared to the BPH tissues. In addition, a higher VEGF expression level (p<0.05) and a lower TSP-1 expression level (p<0.05) in metastatic prostate cancer tissues were observed compared to the localized prostate cancer tissues. A significant inverse correlation was found between the TSP-1 and VEGF expression levels. There was a significant association between the VEGF expression level and the p53 status (p<0.05), but the TSP-1 expression level was not associated with the p53 status. CONCLUSIONS: These results show that angiogenic factors including VEGF and TSP-1 might play an important role in the development and progression of prostate cancer. These changes appear to be influenced by the p53 status.
Angiogenesis Inducing Agents ; Humans ; Immunohistochemistry ; Prostate* ; Prostatic Hyperplasia* ; Prostatic Neoplasms* ; Thrombospondin 1 ; Vascular Endothelial Growth Factor A*